IP Library Granted Patent US 7,547,705
Granted Patent B2
US 7,547,705 · App. 11/866,687 · Granted Jun 16, 2009

Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-

Assignees: Sanofi-Aventis; Mitsubishi Pharma Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,547,705
App. No.
11/866,687
Granted
Jun 16, 2009
Kind
B2
Abstract

The invention relates to a dihydrospiro-[cycloalkylamine]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X, Y, R1, R2, R3, R4, o, m, n, p and q are as defined herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

Claims (60)

1. A method of inhibiting the activity of glycogen synthase kinase 3-beta (GSK3-β), which comprises administering to a patient in need of said inhibition a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein:

X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom;

Y represents a bond, a carbonyl group, a methylene group optionally substituted by one or two groups chosen from a C 1-6 alkyl group, a hydroxyl group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group or an amino group;

R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the rings being optionally substituted by a C 1-4 alkyl group, a C 1-4 alkoxy group or a halogen atom;

R2 represents a benzene ring or a naphthalene ring; the rings being optionally substituted by 1 to 4 substituents selected from a C 1-6 alkyl group, a methylenedioxy group, a halogen atom, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a hydroxyl group, a C 1-4 alkoxy group, a nitro, a cyano, an amino, a C 1-5 monoalkylamino group or a C 2-10 dialkylamino group;

R3 represents a hydrogen atom, a C 1-6 alkyl group or a halogen atom;

R4 represents a hydrogen atom, a C 1-4 alkoxy carbonyl group, a C 3-6 cycloalkyl carbonyl group, a benzoyl group, a C 1-6 alkyl group, the groups being optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group or a C 1-4 alkoxy group;

o and m represent 1 to 2;

n represents 0 to 3;

p represents 0 to 2; and

q represents 0 to 2.

2. The method according to claim 1 , wherein R 4 represents a hydrogen atom, a C 1-4 alkoxy carbonyl group, a C 1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group or a C 1-4 alkoxy group.

3. The method according to claim 1 , wherein R1 represents an unsubstituted 4-pyridinyl group or unsubstituted 4-pyrimidinyl group.

4. The method according to claim 3 , wherein

R2 represents a benzene ring, the ring being optionally substituted by 1 to 4 substituents selected from a C 1-3 alkyl group, a halogen atom, a hydroxyl group or a C 1-2 alkoxy group; and

R3 represents a hydrogen atom; and

R4 represents a C 1-4 alkoxy carbonyl group, a C 3-6 cycloalkyl carbonyl group, a benzoyl group or a C 1-3 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom or a hydroxyl group; and

X represents two hydrogen atoms; and

Y represents a carbonyl group or a methylene group optionally substituted by a hydroxyl group; and

p represents 2 and q represents 0.

5. The method according to claim 1 , wherein the compound is selected from the group consisting of:

Ethyl-1′-[(2S)-2-hydroxy-2-phenylethyl]-6′-oxo-8′-(pyridin-4-yl)-1′,3 ′, 4′,6′tetrahydro-1H-spiro[piperidine-4,2′-pyrimido[1,2-a]pyrimidine]-1-carboxylate

Ethyl-6′-oxo-1′-[2-oxo-2-phenylethyl]-8′-(pyridin-4-yl)-1 ′,3′,4′,6′-tetrahydro-1H-spiro[piperidine-4,2′-pyrimido[1,2-a]pyrimidine]-1-carboxylate

1′-[(2S)-2-Hydroxy-2-phenylethyl]-1-methyl-8′-(.pyridin-4-yl)-3′,4′-dihydrospiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1′H-one

1-Methyl-1′-(2-oxo-2-phenylethyl)-8′-(pyridin-4-yl)-3′,4′-dihydrospiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1 H)-one

Ethyl-1′-[(2S)-2-hydroxy-2-phenylethyl]-6′-oxo-8′-(pyrimidin-4-yl)-1′,3′,4′, 6′-tetrahydro-1H-spiro[piperidine-4,2′-pyrimido[1,2-a]pyrimidine]-1-carboxylate

Ethyl-6′-oxo-1′-[2-oxo-2-phenylethyl]-8′-(pyrimidin-4-yl)-1′,3′,4′, 6′-tetrahydro-1H-spiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidine]-1-carboxylate

1-[(2S)-2-Hydroxy-2-phenylethyl]-1-methyl-8′-(pyrimidin-4-yl)-3′,4′,-dihydrospiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1′H)-one

1-(Cyclohexylcarbonyl)-1′-[(2S)-2-hydroxy-2-phenylethyl]-8′-pyridin-4-yl- 3′,4′-dihyclrospiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1′H)-one

1-(Cyclohexylcarbonyl)-1′-(2-oxo-2-phenylethyl)-8′-pyridin-4-yl-3′,4′-dihydrospiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1′H)-one

1-(3-Fluorobenzoyl)-1′-[(2S)-2-hydroxy-2-phenylethy]-8′-pyridin-4-yl-3′, 4′-dihydrospiro[piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1′H)-one

1 (3-Fluorobeuzoyl)-1′-(2-oxo-2-phenylethyl)-8′-pyridin-4-yl-3′,4′-dihydrospiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1′H)-one

1-(Cyclobutylcarbonyl)-1′-[(2S)-2-hydroxy-2-phenylethyl]-8′-pyridin-4-yl-3′, 4′-dihydrospiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1′H)-one

1-(Cyclobutylcarbonyl)-1′-(2-oxo-2-phenylethyl)-8′-pyridin-4-yl-3′,4′- dihydrospiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1′H)-one

1-(Cyclopropylcarbonyl)-1′-[(2S)-2-hydroxy-2-phenylethyl]-8′-pyridin-4-yl-3′, 4′-dihydrospiro[piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1 H)-one

1-( Cyclopropylcarbonyl)-1′-(2-oxo-2-phenylethyl)-8′-pyridin-4-yl-3′,4′- dihydrospiro [piperidine-4,2′-pyrimido[1,2-a]pyrimidin]-6′(1′H)-one

1-Methyl-1-(2-oxo-2-phenylethyl)-8′-(pyrimidin-4-yl)-3′,4′. dihydrospiro[piperidine-4,2′-pyrimido[1,2a]pyrimidin]′6′(1′H)-one

Ethyl 1-[(2S)-2-hydroxy-2-phenylethyl]-6-oxo-8-(pyridin-4-yl)-1,3,4,6 -tetrahydro-1′H-spiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidine]-1′-carboxylate

Ethyl 6-oxo-1-(2-oxo-2-phenylethyl)-8-(pyridin-4-yl)-1,3,4,6-tetrahydro-1′H-spiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidine]-1′-carboxylate

1-[(2 S)-2-hydroxy-2-phenylethyl]-1′-methyl-8-(pyridin-4-yl)-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one 1′-Methyl-1-(2-oxo-2-phenylethyl)-8-(pyridin-4-yl)-3,4- dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1H)-one

Ethyl 1-[(2S)-2-hydroxy-2-phenylethyl]-6-oxo-8-pyrimidin-4-yl-1,3,4,6 -tetrahydro-1′H-spiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidine]-1′-carboxylate

Ethyl 6-oxo-1-(2-oxo-2-phenylethyl)-8-pyrimidin-4-yl-1,3,4,6-tetrahydro-1′H-spiro [pyrimido [1,2-a]pyrimidine-2,3′-pyrrolidine]-1′-carboxylate

1′-(3-Fluorobenzoyl)-1-[(2S)-2-hydroxy-2-phenylethyl]-8-pyrimidin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(3-Fluorobenzoyl)-1-(2-oxo-2-phenylethyl)-8-pyrimidin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(3-Fluorobenzoyl)-1-[(2S)-2-hydroxy-2-phenylethyl]-8-pyridin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(3-Fluorobenzoyl)-1-(2-oxo-2-phenylethyl)-8-pyridin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1H)-one

1′-(Cyclopropylcarbonyl)-1-[(2S)-2-hydroxy-2-phenylethyl]-8-pyridin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(Cyclopropylcarbonyl)-1-(2-oxo-2-phenylethyl)-8-pyridin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1H)-one

1′-(Cyclopropylcarbonyl)-1-[(2 S)-2-hydroxy-2-phenylethy]-8-pyrimidin-4-yl- 3,4-dihydrospiro [pyrimidot 1,2-a]pyrimidine-2,3′-pyrrolidinl-6(1 H)-one

1′-(Cyclopropylcarbonyl)-1-(2-oxo-2-phenylethyl)-8-pyrimidin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(Cyclobutylcarbonyl)-1-[(2S)-2-hydroxy-2-phenylethyl]-8-pyrimidin-4-yl-3,4-dihydrospiro[pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(Cyclobutylcarbonyl)-1-(2-oxo-2-phenylethyl)-8-pyrimidin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(Cyclobutylcarbonyl)-1-[(2S)-2-hydroxy-2-phenylethyl]-8-pyridin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(Cyclobutylcarbonyl)-1-(2-oxo-2-phenylethyl)-8-pyridin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(Cyclohexylcarbonyl)-1-[(2 S)-2-hydroxy-2-phenylethyl]-8-pyridin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one

1′-(Cyclohexylcarbonyl)-1-(2-oxo-2-phenethyl)-8-pyridin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1H)-one

1′-(Cyclohexylcarbonyl)-1-[(2 S)-2-hydroxy-2-phenylethyl]-8-pyrimidin-4-yl- 3,4-dihydrospiro[pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1H)-one

1′-(Cyclohexylcarbonyl)-1-(2-oxo-2-phenethyl)-8-pyrimidin-4-yl-3,4-dihydrospiro [pyrimido[1,2-a]pyrimidine-2,3′-pyrrolidin]-6(1 H)-one;

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2009
From: CHEREZE, NATHALIE; LOCHEAD, ALISTAIR; SAADY, MOURAD; SLOWINSKI, FRANCK; YAICHE, PHILIPPE
To: SANOFI-AVENTIS; MITSUBISHI PHARMA CORPORATION
Reel/Frame 022386/0138 →
Priority Claims (1)
EP 03293236 · Dec 19, 2003 · regional
Continuity (3)
Division 1142355700 · Jun 12, 2006
Continuation PCTEP200401484600 · Dec 17, 2004
Related Publication 20080081820A1 · Apr 3, 2008